VEGFA and metastatic colorectal cancer: Targeted vascular endothelial growth factor (VEGF) inhibitors or epidermal growth factor receptor (EGFR) monoclonal antibodies such as bevacizumab, aflibercept, cetuximab, and panitumumab have been demonstrated to increase pCR rates and improve prognoses for metastatic colorectal cancer (mCRC) patients 13, 14, 15, 16.